Elsevier

European Urology

Volume 74, Issue 1, July 2018, Pages 63-65
European Urology

Platinum Priority – Editorial
Referring to the article published on pp. 57–62 of this issue
Improving the Cost Efficiency of PD-1/PD-L1 Inhibitors for Advanced Urothelial Carcinoma: A Major Role for Precision Medicine?

https://doi.org/10.1016/j.eururo.2018.03.015Get rights and content

Section snippets

Conflicts of interest

G. Sonpavde: grants to institution—Boehringer-Ingelheim, Bayer, Onyx-Amgen, Pfizer, and Merck; consultant for Pfizer, Genentech, Novartis, Argos, Merck, Sanofi, Astellas/Agensys, Clinical Care Options, Astrazeneca, Biotheranostics, Exelixis, Bristol-Myers-Squibb, Janssen, Amgen, and Eisai; speaker/author for Uptodate, National Comprehensive Cancer Network (NCCN), Physicians Education Resource (PER), Onclive, and Research to Practice (RTP). G. Dranitsaris: advisory board—Bristol-Myers-Squibb. A.

Cited by (3)

  • Multiomics analysis of tumor mutational burden across cancer types

    2021, Computational and Structural Biotechnology Journal
    Citation Excerpt :

    Compared with those receiving traditional treatment, patients receiving immune checkpoint inhibitor (ICI) treatment may achieve long-term survival. However, ICIs are not effective in all cancer patients [4–6], and most cancer patients treated with ICIs do not benefit. It is vital to determine precise biomarkers to predict the efficacy of immunotherapy.

View full text